Biomedix Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Biomedix's estimated annual revenue is currently $72.2M per year.(i)
  • Biomedix's estimated revenue per employee is $297,000

Employee Data

  • Biomedix has 243 Employees.(i)
  • Biomedix grew their employee count by 36% last year.

Biomedix's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP, ProductReveal Email/Phone
3
Director, Clinical DevelopmentReveal Email/Phone
4
Customer Service ManagerReveal Email/Phone
5
Hospital Account Executive - SoutheastReveal Email/Phone
6
Senior Clinical SpecialistReveal Email/Phone
7
Strategic Account ExecutiveReveal Email/Phone
8
Health Plan Partnerships ExecutiveReveal Email/Phone
9
Client Services AssociateReveal Email/Phone
10
Strategic Account SpecialistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.3M346%N/AN/A
#2
$279320M151713-45%N/AN/A
#3
$0.4M3200%N/AN/A
#4
$15.3M637%N/AN/A
#5
$13.4M55-4%N/AN/A
#6
$72.8M24510%N/AN/A
#7
$10.4M484%N/AN/A
#8
$8.9M41-5%N/AN/A
#9
$14.3M5911%N/AN/A
#10
$8.6M40-11%N/AN/A
Add Company

What Is Biomedix?

Biomedix is a provider of front-line diagnostic solutions for delivering value-based care. We offer a mobile health assessment platform that centralizes data for analyzing population health across multiple chronic conditions, and supports a variety of diagnostic devices. Biomedix is the maker of PADnet, the market leader in front-line diagnostics for peripheral vascular disease. PADnet is the only diagnostic device that can support the identification of peripheral artery disease (PAD) and chronic venous insufficiency (CVI) through a unique collaborative care model, which enables the cost-effective delivery of care that optimizes patient outcomes.

keywords:N/A

N/A

Total Funding

243

Number of Employees

$72.2M

Revenue (est)

36%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M2434%N/A
#2
$72.8M24510%N/A
#3
$67.9M24616%N/A
#4
$15M2489%N/A
#5
$80.5M27138%N/A